Dr. Amanda Lorene Wright is a pharmacist who is specialized in Oncology in Boise, Idaho. Patients can reach her at 190 E Bannock St, Boise or contact her on 208-381-2530. Active license number of Dr. Amanda Lorene Wright is P7801 for Oncology in Idaho. Dr. Amanda Lorene Wright is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Dr. Amanda Lorene Wright speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Dr. Amanda Lorene Wright
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Female
Location:
190 E Bannock St, Boise, Idaho, 83712-6241
Phone:
208-381-2530
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Amanda Lorene Wright are as mentioned below.
NPI Number:
1376181743
NPI Enumeration Date:
17 Dec, 2019
NPI Last Update On:
17 Dec, 2019
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Amanda Lorene Wright are as mentioned below.
Specialization
License Number
State
Status
Oncology
P7801
Idaho
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
100 E Idaho St, Boise, Idaho
Zip:
83712-6267
Phone Number:
208-381-4586
Fax Number:
--
Patients can reach Dr. Amanda Lorene Wright at 190 E Bannock St, Boise, Idaho or can call on phone at 208-381-2530.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.